Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer
    • Publication Information:
      Publication: <2009-> : [New York] : Elsevier
      Original Publication: Dallas, Tex. : Cancer Information Group, c2005-
    • Subject Terms:
      Quality of Life*; Anxiety Disorders/*epidemiology ; Cancer Survivors/*statistics & numerical data ; Depressive Disorder/*epidemiology ; Fatigue/*epidemiology ; Leydig Cells/*pathology ; Sexual Dysfunction, Physiological/*epidemiology ; Testicular Neoplasms/*therapy; Aged ; Anxiety Disorders/blood ; Depressive Disorder/blood ; Fatigue/blood ; Follow-Up Studies ; Humans ; Incidence ; Leydig Cells/metabolism ; Luteinizing Hormone/blood ; Male ; Middle Aged ; Prognosis ; Sexual Dysfunction, Physiological/blood ; Testicular Neoplasms/pathology ; Testosterone/blood
    • Abstract:
      Background: Compensated Leydig cell (LC) dysfunction, defined by elevated serum levels of luteinizing hormone (LH) in combination with normal total testosterone levels, is common in testicular cancer (TC) survivors. The association between this condition and quality of life is unknown. We aimed to clarify if TC survivors with compensated LC dysfunction have impaired quality of life.
      Patients and Methods: In total, 147 long-term TC survivors were included. On the basis of a single measurement of testosterone and LH, compensated LC dysfunction was defined by age-adjusted levels of LH above normal range combined with testosterone levels within the normal range. Quality-of-life outcomes including sexual function, anxiety and depression, fatigue, and overall self-evaluated quality of life were compared between patients with and without compensated LC dysfunction with adjustment for age.
      Results: In total, 60 TC survivors had compensated LC dysfunction and 87 TC survivors had normal LC function. TC survivors with compensated LC dysfunction had lower serum levels of total testosterone (11 vs. 13 nmol/L, P = .016). There were no significant differences in the investigated quality-of-life outcomes (anxiety, depression, sexual function, fatigue) between the 2 groups.
      Conclusion: Compensated LC dysfunction in TC survivors was not associated with symptoms of depression, anxiety, sexual dysfunction, fatigue, or impaired overall self-evaluated quality of life. Limitations include the few cases of symptoms of depression (n = 7). Our findings do not suggest that testosterone substitution is indicated in TC survivors with compensated LC dysfunction.
      (Copyright © 2018 Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: Late effects*; Subclinical hypogonadism*; Testicular cancer*; Testosterone*; Testosterone substitution*
    • Accession Number:
      3XMK78S47O (Testosterone)
      9002-67-9 (Luteinizing Hormone)
    • Publication Date:
      Date Created: 20181009 Date Completed: 20190807 Latest Revision: 20190807
    • Publication Date:
      20221213
    • Accession Number:
      10.1016/j.clgc.2018.09.004
    • Accession Number:
      30293923